Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Encorafenib and binimetinib followed by radiotherapy for patients with BRAFV600-mutant melanoma and brain metastases (E-BRAIN/GEM1802 phase II study).
Márquez-Rodas I, Álvarez A, Arance A, Valduvieco I, Berciano-Guerrero MÁ, Delgado R, Soria A, Lopez Campos F, Sánchez P, Romero JL, Martin-Liberal J, Lucas A, Díaz-Beveridge R, Conde-Moreno AJ, Álamo de la Gala MDC, García-Castaño A, Prada PJ, González Cao M, Puertas E, Vidal J, Foro P, Aguado de la Rosa C, Corona JA, Cerezuela-Fuentes P, López P, Luna P, Aymar N, Puértolas T, Sanagustín P, Berrocal A. Márquez-Rodas I, et al. Among authors: cerezuela fuentes p. Neuro Oncol. 2024 Nov 4;26(11):2074-2083. doi: 10.1093/neuonc/noae116. Neuro Oncol. 2024. PMID: 38946469 Free PMC article. Clinical Trial.
Frequency and characteristics of familial melanoma in Spain: the FAM-GEM-1 Study.
Márquez-Rodas I, Martín González M, Nagore E, Gómez-Fernández C, Avilés-Izquierdo JA, Maldonado-Seral C, Soriano V, Majem-Tarruella M, Palomar V, Maseda R, Martín-Carnicero A, Puertolas T, Godoy E, Cerezuela P, Ochoa de Olza M, Campos B, Perez-Ruiz E, Soria A, Gil-Arnaiz I, Gonzalez-Cao M, Galvez E, Arance A, Belon J, de la Cruz-Merino L, Martín-Algarra S; Spanish Multidisciplinary Group of Melanoma (GEM). Márquez-Rodas I, et al. PLoS One. 2015 Apr 13;10(4):e0124239. doi: 10.1371/journal.pone.0124239. eCollection 2015. PLoS One. 2015. PMID: 25874698 Free PMC article.
SARS-CoV-2 infection in patients with melanoma: results of the Spanish Melanoma Group registry.
Gonzalez-Cao M, Puertolas T, Martinez-Vila C, Carrera C, Maldonado Seral C, Rodríguez-Jiménez P, Sequero S, Cerezuela-Fuentes P, Feltes Ochoa R, Muñoz E, Antoñanzas Basa M, Martín-Liberal J, Soria A, Francisco Rodriguez Moreno J, Marquez-Rodas I, Lopez Criado P, Luis Manzano J, Lopez-Castro R, Ayala de Miguel P, Villalobos L, Martin Algarra S, Gonzalez-Barrallo I, Boada A, García Castaño A, Puig S, Crespo G, Luna Fra P, Aguayo Zamora C, Feito Rodríguez M, Valles L, Drozdowskyj A, Gardeazabal J, Antonio Fernandez-Morales L, Rodrigo A, Cruz R, Yelamos O, Rubio B, Mujica K, Provencio M, Berrocal A; Spanish Melanoma Group (GEM). Gonzalez-Cao M, et al. Among authors: cerezuela fuentes p. Clin Transl Oncol. 2023 Mar;25(3):768-775. doi: 10.1007/s12094-022-02985-7. Epub 2022 Dec 24. Clin Transl Oncol. 2023. PMID: 36566266 Free PMC article.
Adjuvant dabrafenib and trametinib for patients with resected BRAF -mutated melanoma: DESCRIBE-AD real-world retrospective observational study.
Manzano JL, Martin-Liberal J, Fernández-Morales LA, Benítez G, Medina Martínez J, Quindós M, García-Castaño A, Fernández O, Simo RV, Majem M, Bellido L, Ayala de Miguel P, Campos B, Espinosa E, Macías Cerrolaza JA, Gil-Arnaiz I, Lorente D, Rodriguez-Lescure A, Perez VN, López Castro R, Gramaje MG, Puértolas T, Rodriguez Moreno JF, Espasa Font L, Belaustegui Ferrández G, Cerezuela-Fuentes P. Manzano JL, et al. Among authors: cerezuela fuentes p. Melanoma Res. 2023 Oct 1;33(5):388-397. doi: 10.1097/CMR.0000000000000888. Epub 2023 Mar 28. Melanoma Res. 2023. PMID: 36988401 Free PMC article.
Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis.
Cerezuela-Fuentes P, Gonzalez-Cao M, Puertolas T, Manzano JL, Maldonado C, Yelamos O, Berciano-Guerrero MA, Martin-Liberal J, Muñoz-Couselo E, Espinosa E, Drozdowskyj A, Berrocal A, Soria A, Marquez-Rodas I, Martin-Algarra S, Quindos M, Puig S; Spanish Melanoma Group (GEM). Cerezuela-Fuentes P, et al. Clin Transl Oncol. 2025 Jan;27(1):386-391. doi: 10.1007/s12094-024-03583-5. Epub 2024 Jul 1. Clin Transl Oncol. 2025. PMID: 38951438
Frequency and Clinicopathological Profile Associated with Braf Mutations in Patients with Advanced Melanoma in Spain.
Lopez-Martin JA, Arance Fernández A, Ríos-Martín JJ, Hernández-Losa J, Alós Hernández L, Cerezuela Fuentes P, Ortiz Reina S, Ortega Izquierdo E, Martí RM, Soberino García J, Ferrer Fábrega B, Rodríguez Peralto JL; ABSOLUT-BRAF Study Group. Lopez-Martin JA, et al. Among authors: cerezuela fuentes p. Transl Oncol. 2020 Jun;13(6):100750. doi: 10.1016/j.tranon.2020.100750. Epub 2020 May 15. Transl Oncol. 2020. PMID: 32422543 Free PMC article.
Characteristics and outcomes of advanced melanoma patients with complete response and elective discontinuation of first-line anti-programmed death-1 monotherapy: A real-world multicentre observational cohort study.
Ochenduszko S, García Sanchez J, Fita MJJ, González-Barrallo I, Herrero Colomina J, Mujika K, Beveridge RD, Martínez SR, Lafuente BS, Tomas AC, Jaime AB, Cerezuela Fuentes P, Fra PL, Peeters AG, Meana García JA, García MAA, Altozano JP, Cancela M, Puchades AM, Roca FF, Maiques IM. Ochenduszko S, et al. Among authors: cerezuela fuentes p. Pigment Cell Melanoma Res. 2023 Sep;36(5):388-398. doi: 10.1111/pcmr.13093. Epub 2023 May 27. Pigment Cell Melanoma Res. 2023. PMID: 37243929
Real-World Evidence of Adjuvant Immunotherapy in Resected Stage III and IV Melanoma Patients: CADIM Trial Final Results. Experience from 2 Tertiary Referral Centers.
Morellá Fernández M, Balsalobre Yago J, Martínez García J, Peláez Gutiérrez M, López Muñoz A, Silvestre Ballesta AI, Sánchez Lafuente B, Martínez Martín I, Cerezuela Fuentes P. Morellá Fernández M, et al. Among authors: cerezuela fuentes p. Actas Dermosifiliogr. 2024 Sep 11:S0001-7310(24)00719-1. doi: 10.1016/j.ad.2024.07.021. Online ahead of print. Actas Dermosifiliogr. 2024. PMID: 39271008 English, Spanish.
[Translated article] Real-World Evidence of Adjuvant Immunotherapy in Resected Stage III and IV Melanoma Patients: CADIM Trial Final Results. Experience From 2 Tertiary Referral Centers.
Morellá Fernández M, Balsalobre Yago J, Martínez García J, Peláez Gutiérrez M, López Muñoz A, Silvestre Ballesta AI, Sánchez Lafuente B, Martínez Martín I, Cerezuela Fuentes P. Morellá Fernández M, et al. Among authors: cerezuela fuentes p. Actas Dermosifiliogr. 2024 Dec 24:S0001-7310(24)00997-9. doi: 10.1016/j.ad.2024.12.008. Online ahead of print. Actas Dermosifiliogr. 2024. PMID: 39725280 English, Spanish.
20 results